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Abstract:  The  anti-tumor  effects  of  11-dehydrosinulariolide,  an  active  ingredient  
isolated  from  soft  coral  Sinularia  leptoclados,  on  CAL-27  cells  were  investigated  in  
this  study.  In  the  MTT  assay  for  cell  proliferation,  increasing  concentrations  of 
11-dehydrosinulariolide  decreased  CAL-27  cell  viability.  When  a  concentration  of 
1.5 µg /mL of 11-dehydrosinulariolide was applied, the CAL-27 cells viability was reduced 
to a level of 70% of the control sample. The wound healing function decreased as the 
concentration of 11-dehydrosinulariolide increased. The results in this study indicated that 
treatment with 11-dehydrosinulariolide for 6 h significantly induced both early and late 
apoptosis of CAL-27 cells, observed by flow cytometric measurement and microscopic 
fluorescent observation. A comparative proteomic analysis was conducted to investigate the 
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effects of 11-dehydrosinulariolide on CAL-27 cells at the molecular level by comparison 
between the  protein profiling (revealed on a 2-DE  map)  of CAL-27 cells treated  with 
11-dehydrosinulariolide  and  that  of  CAL-27  cells  without  the  treatment.  A  total  of  
28 differential proteins (12 up-regulated and 16 down-regulated) in CAL-27 cells treated 
with 11-dehydrosinulariolide have been identified by LC-MS/MS analysis. Some of the 
differential proteins are associated with cell proliferation, apoptosis, protein synthesis, protein 
folding, and energy metabolism. The results of this study provided clues for the investigation 
of biochemical mechanisms of the anti-tumor effects of 11-dehydrosinulariolide on CAL-27 
cells and could be valuable information for drug development and progression monitoring of 
oral squamous cell carcinoma (OSCC). 
Keywords: 11-dehydrosinulariolide; CAL-27 cells; proteomic analysis 
 
1. Introduction 
Oral squamous cell carcinoma (OSCC), the most widespread malignant neoplasm of the oral cavity, 
is the sixth most prevalent malignancy worldwide and the fourth most common cancer among the 
Taiwanese male population [1]. OSCC can be treated by surgical operation, chemotherapy, radiotherapy, 
and combinations of the treatments; however, patients usually have poor prognosis, i.e., 50% survival 
rate in 5 years [2,3]. Studies indicated that the metabolite from soft coral such as steroids, terpenoids [4,5], 
and diterpenes have antimicrobial, antitumor, and HIV-inhibitory activities [6]. Acylspermidines from 
the Okinawan soft coral, Sinularia sp. expressed strong cytotoxicity against human tumor cell lines 
along  with  the  induction  of  apoptotic  phenomena  [7].  Three  norcembrane-based  diterpenoid, 
1-epi-leptocladolide A, leptocladolides A, and 7E-leptocladolide A have been isolated from soft coral 
Sinularia leptoclados. They have shown significant cytotoxic activity against KB and Hepa59T/VGH 
cancer lines [8]. Despite the numerous reports, the mechanisms of anti-cancer effects of the extracts 
from soft coral are still not well understood. 
Analysis of the protein profilings of the cells and tissues by proteomic analysis has been rapidly 
developed. Proteomic analysis provides a systematic approach to reveal the overall protein expression 
along with qualitative and quantitative analysis of a specific protein. Comparative proteomic analysis 
can be used to monitor the up-regulation and down-regulation of proteins under treatments with different 
compounds in comparison with the control. The results could provide valuable information for drug 
development and monitoring disease progression [9,10]. In this study, comparative proteomic analysis 
with  two-dimensional  gel  electrophoresis  (2-DE)  was  performed  to  investigate  the  effects  of 
11-dehydrosinulariolide  on  the  oral  caner  cells.  The  chemical  structure  and  the  NMR  spectra  of 
11-dehydrosinulariolide were shown in Figure 1. It is an active compound isolated from the soft coral 
Sinularia leptoclados [11]. Differential proteins were detected by comparing between the overall protein 
expression of CAL-27 cells treated with 11-dehydrosinulariolide and that of CAL-27 cells without 
treatment. The biochemical functions of the differential proteins were also explored.  Mar. Drugs 2011, 9  
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Figure  1.  (a)  Chemical  structure  of  11-dehydrosinulariolide;  (b)  1H  NMR  spectrum  
of  11-dehydrosinulariolide  in  CDCl3  at  400  MHz;  (c)  13C  NMR  spectrum  of 
11-dehydrosinulariolide in CDCl3 at 100 MHz. 
(a) 
 
(b) 
 
(c) 
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2. Results and Discussion 
2.1. The Cytotoxic Effects of 11-Dehydrosinulariolide on CAL-27 Cells 
The CAL-27 cells were treated with 11-dehydrosinulariolide of various concentrations (0.5, 1.0, 1.5, 
2.0 µ g/mL) for 24 h and the viabilities of the cells were determined by MTT assay. (Figure 2) The results 
indicated that increasing concentrations of 11-dehydrosinulariolide decreased CAL-27 cell viability. 
When a concentration of 1.5 µ g/mL of 11-dehydrosinulariolide was applied, the CAL-27 cell viability 
was reduced to a level of 70% of the control sample. The morphological changes of the cells treated with 
11-dehydrosinulariolide were observed by inverted light microscopy. The untreated cells that grew looked 
compact and smooth, on the other hand, the cells treated with 1.5 µ g/mL of 11-dehydrosinulariolide 
showed shrinkage and a distinct decreased cell population compared with the counterpart (Figure 3). The 
effect of 11-dehydrosinulariolide on CAL-27 cell was also examined by wound healing assay. The 
wound healing function decreased as the concentrations of 11-dehydrosinulariolide increased (Figure 4). 
Figure 2. Viability of CAL-27 cells treated with 11-dehydrosinulariolide. Cells were treated 
with the indicated concentrations of 11-dehydrosinulariolide. Inhibition of cell proliferation 
was assessed by MTT assay as described in the Materials and Methods Section. The data 
were represented as the means ±  SEM from three independent experiments (# P < 0.01 and  
* P < 0.001). 
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Figure 3. Morphological changes of CAL-27 cells treated with different concentrations of 
11-dehydrosinulariolide  for  24  h.  (A)  control  sample  (B)  treated  with  1.5  µ g/mL  of 
11-dehydrosinulariolide. 
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Figure 4. Wound healing assay of CAL-27 cells treated with 11-dehydrosinulariolide. The 
cancer cells in the areas between the two solid lines were those migrated in the gaps during 
the indicated time periods. Increased 11-dehydrosinulariolide concentration decreased the 
migration ability of CAL-27 cells. 
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2.2. Apoptosis of CAL-27 Treated with 11-Dehydrosinulariolide  
To  investigate the cytotoxicity effect of 11-dehydrosinulariolide for  the induction  of apoptosis, 
CAL-27 cells were treated with 11-dehydrosinulariolide and analyzed by flow cytometry. The apoptosis 
rate of 1.75% for CAL-27 was observed after the treatment with 1.5 µ g/mL 11-dehydrosinulariolide for 
6  h  versus  the  apoptosis  rate  of  0.2%  for  the  control  sample  (lower  right  of  Figure  5).  The  late 
apoptosis/necrosis cell rate of 3.68% was observed for CAL-27 after the treatment with 1.5 µ g/mL 
11-dehydrosinulariolide versus the late apoptosis/necrosis cell rate of 0.93% for the control (upper right 
of Figure 5). These results clearly indicated that treatment with 11-dehydrosinulariolide significantly 
induced both early and late apoptosis of CAL-27 cells, determined by flow cytometric measurement and 
microscopic fluorescent observation (Figure 5C). 
After treatment with 11-dehydrosinulariolide for 6 h, 1 ×  10
6 adherent cells were trypsinized and 
incubated with FITC-conjugated annexin V and propidium iodide(PI) for 15 min in the dark. Cells were 
analyzed by flow cytometry. In the gate areas, the upper right panel was for the population of late 
apoptotic cells and the lower right panel was for the early apoptotic cells with increased annexin V. The 
results indicated the treatment with 11-dehydrosinulariolide for 12 h significantly induced early and late 
apoptosis of CAL-27 cells.  Mar. Drugs 2011, 9  
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Figure 5. Flow cytometry analysis of the induced apoptosis of CAL-27cells treated with 
11-dehydrosinulariolide  by  annexin  V-FITC/PI  expression.  (A)  CAL-27  cells  were  
treated  without  11-dehydrosinulariolide  treatment;  (B)  The  cells  were  treated  with 
11-dehydrosinulariolide  at  1.5  µ g/mL,  then  collected  for  staining  with  FITC-conjugated 
annexin V; (C) the fluorescently visualized cells were observed through florescent microscope. 
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2.3. Proteomic Analysis of CAL-27 Cells Treated with 11-Dehydrosinulariolide  
The  CAL-27  cells  were  harvested  after  being  treated  with  a  1.5 µ g/mL  solution  of 
11-dehydrosinulariolide.  The  proteins  were  extracted  from  cultured  cells  with  lysis  buffer.  The 
supernatants were collected and the proteins were precipitated by TCA/Acetone. The 2-DE maps of the 
CAL-27 cells treated with 11-dehydrosinulariolide were compared with those of the control samples to 
examine the effect of 11-dehydrosinulariolide on CAL-27. The 2-DE were run with a loading of 50 µg 
protein (pI 4–7) and visualized by silver staining (Figures 6 and 7). PDQuest image analysis software 
(Bio-Rad) was employed for detecting the differential protein spots which were defined as the proteins 
showing a more than 1.5 fold intensity difference in 2-DE maps between the treated CAL-27 cells and 
the control samples. The protein identification was carried out by LC-MS/MS analysis after in gel 
digestion.  MASCOT  protein  identification  search  software  was  used  for  the  identification  of  the 
differential protein spots. A total of 28 differential protein spots were successfully identified. A list of 
the identified proteins with their MASCOT score, MS/MS matched sequences, apparent and theoretical 
MW, pI, coverage, and fold of change in expression level (up-regulation or down-regulation) were 
shown in Table 1.  Mar. Drugs 2011, 9  
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Figure 6. The 2-DE maps of CAL-27 cells treated with 11-dehydrosinulariolide and the 
control sample. (A) control (B) treated with 1.5 µ g/mL 11-dehydrosinulariolide for 24 h. 
Proteins spots marked on the maps were considered differentially expressed and identified 
by LC-MS/MS. The results are representatives of three independent runs. 
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Figure 7. Enlarged 2-DE map of the 28 differential proteins in CAL-27 cells treated with 
11-dehydrosinulariolide. Solid arrows point the up-regulated proteins and dashed arrows 
point the down-regulated proteins. 
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Table  1.  Identities  of  the  differential  proteins  in  CAL-27  cells  treated  with 
11-dehydrosinulariolide analyzed by LC-MS/MS. 
Spot 
no. 
Protein name 
Accessio
n no. 
Calculate 
Mr/pI 
Peptide 
matched 
Sequence 
covered % 
MASCOT 
score 
Regulation 
(fold-change) * 
1  Reticulocalbin-1   Q15293  38.86/4.86  7  28  148  −2.7 
2  Protein SET (Phosphatase 2A 
inhibitor I2PP2A) 
Q01105  33.47/4.23  5  20  87  +2.2 
3  78 kDa glucose-regulated  
protein precursor 
P11021  72.28/5.07  8  8  152  −2.0 
4  Heterogeneous nuclear 
ribonucleoprotein F 
P52597  45.64/5.38  29  35  345  −2.1 
5  60 kDa heat shock protein  P10809  61.02/5.70  43  46  753  −3.7 
6  Actin-like protein 6A  O96019  47.43/5.39  19  23  83  −2.2 
7  Proteasome subunit beta  
type 4 precursor  
P28070  29.18/5.72  6  35  118  −2.1 
8  F-actin capping protein subunit beta  P47756  31.33/5.36  22  31  242  −2.8 
9  Peptidyl-prolyl cis-trans  
isomerase A 
P62937  18.0/7.68  2  9  49  +2.3 
10  Protein disulfide-isomerase  
A3 precursor 
P14136  56.75/5.98  84  57  1168  +2.2 
11  Purine nucleoside phosphorylase  P00491  32.09/6.45  9  23  208  −6.4 
12  UPF0160 protein MYG1  Q9HB07  42.41/6.25  2  5  73  +3.8 
13  Xaa-Pro dipeptidase  P12955  54.51/5.64  11  14  199  −2.0 
14  SPFH domain-containing  
protein 2 precursor 
O94905  37.81/5.47  17  6  104  +2.2 
15  60S acidic ribosomal protein P0  P05388  34.25/5.71  88  44  933  −2.7 
16  Ubiquinol cytochrome c reductase 
complex core protein 1 
P31930  52.61/5.94  23  28  296  −2.6 
17  40S ribosomal protein SA  P08865  32.83/4.79  72  51  930  −1.8 
18  Nascent polypeptide-associated 
complex subunit alpha 
Q13765  23.37/4.52  25  32  494  −3.1 
19  Nucleolin  P19338  76.56/4.6  51  34  519  +4.1 
20  Transitional endoplasmic  
reticulum ATPase 
P55072  89.26/5.14  127  46  1117  −1.6 
21  Neutral alpha-glucosidase  
AB precursor 
Q14697  106.8/5.74  85  39  988  +3.0 
22  Isocitrate dehydrogenase  
subunit alpha 
P50213  39.56/6.47  35  28  413  −3.8 
23  Fructose-bisphosphate aldolase A  P04075  39.39/8.0  103  60  1330  −9.0 
24  Prohibitin  P35232  29.78/5.57  23  36  115  +2.4 
25  Lactoylglutathione lyase  Q04760  20.7/5.24  52  56  344  +1.5 
26  Translationally-controlled tumor 
protein (TCTP) 
P13693  19.58/4.84  35  52  198  +2.0 
27  Inorganic pyrophosphatase  Q15181  32.63/5.54  45  55  530  +3.0 
28  Protein DJ-1  Q99497  19.87/6.33  38  65  238  +2.0 
* Regulations (fold-changes) of differentially expression proteins are expressed at 24 h treatment of 11-dehydrosinulariolide. Mar. Drugs 2011, 9  
 
1262 
The  varied  expression  of  proteins  distributed  throughout  the  entire  gels  indicated  that  multiple 
clusters of proteins were involved in the effects of 11-dehydrosinulariolide on CAL-27 cell. A total of  
12 differential proteins were up-regulated after 11-dehydrosinulariolide treatment. They were protein 
SET, protein disulfide isomerase A3 (PDIA3), peptidyl-prolyl cis-trans isomerase A, UPF0160 protein 
MYG1,  SPFH  domain-containing  protein  2  precursor,  nucleolin,  neutral  alpha-glucosidase  AB 
precursor, prohibitin, translationally-controlled tumor protein, inorganic pyrophosphatase, protein DJ-1, 
and  lactoylglutathione  lyase.  A  total  of  16  differential  proteins  were  down-regulated  after 
11-dehydrosinulariolide  treatment.  They  were  reticulocalbin-1,  78  kDa,  glucose-regulated  protein 
(GRP78), heterogeneous nuclear ribonucleoprotein F (hnRNP F), 60 kDa heat shock protein (Hsp60),  
actin-like protein 6A, proteasome subunit beta type 4 precursor, F-actin capping protein subunit beta,  
purine  nucleoside  phosphorylase,  Xaa-Pro  dipeptidase,  60S  acidic  ribosomal  protein  P0, 
ubiquinol-cytochrome-c  reductase  complex  core  protein  1  (UQCRC1),  40S  ribosomal  protein  SA, 
transitional  endoplasmic  reticulum  ATPase,  isocitrate  dehydrogenase  subunit  alpha, 
fructose-bisphosphate aldolase A, and nascent polypeptide-associated complex subunit alpha. 
2.4. Validation by Western Blotting 
The identities of PDIA3, Hsp60, GRP78, UQCRC1 and prohibitin were further validated by western 
blotting (Figure 8). The results were in agreement with the 2-DE data. 
Figure 8. Western blotting analysis of PDIA3, Hsp60, UQCRC1, GRP78 and prohibitin of 
CAL-27 cells treated with increasing concentrations of 11-dehydrosinulariolide for 24 h. 
GAPDH was used as the internal control. 
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2.5. Discussion 
Comparative proteomic analysis can reveal the changes of protein expression of a proteome with a 
specific  treatment  by  comparison  with  the  control  sample.  The  data  could  provide  clues  for  the 
investigation of the effects of the specific treatment and the further understanding of the mechanisms at 
molecular level. There were reports about the antimicrobial, antiviral, and cytotoxic properties of soft Mar. Drugs 2011, 9  
 
1263 
corals [12–14]. It has also been reported that some chemical compounds from soft coral exert anti-tumor 
activities [8,15,16]. Most of the studies focused on the cytotoxicity of soft corals. There were fewer 
reports about the anti-tumor effects of active compounds in soft coral. In this study, the anti-cancer 
effects of 11-dehydrosinulariolide on CAL-27 cells by MTT assay, flow cytometry, and wound healing 
assay have been investigated. The proteins related with the effect of 11-dehydrosinulariolide have been 
identified by comparative proteomic analysis. The inhibitory effect of 11-dehydrosinulariolide on cell 
growth  regarding  dose-dependent,  cytotoxicity  or  the  induction  of  apoptosis  were  also  assessed.  
A  total  of  28  differential  proteins  have  been  identified  including  12  up-regulated  proteins  and  
16 down-regulated proteins. It was found that some proteins such as PDIA3, Hsp60, GRP78, hnRNP F, 
UQCRC1 and prohibitin, are associated with apoptosis or inhibition of cancer cell growth. 
2.5.1. Protein Disulfide Isomerase A3 (PDIA3) 
Protein disulfide isomerase A3, a member of the PDI family, participates in the oxidation, reduction, 
and isomerization of disulfide bonds for correct folding of secretory proteins before modification and 
transport in the endoplasmic reticulum [17]. It has been reported that PDI is induced by endoplasmic 
reticulum (ER) stress resulting from interference with Ca
2+ homeostasis, inhibition of the formation of 
disulfide bond, and oxidative stress to relieve the accumulation of misfolded or unfolded proteins in the 
ER [18]. Study indicated that the accumulation of misfolded proteins in the ER initiates unfolded protein 
response (UPR) which adjusts ER protein folding capacity to promote cell survival. When homeostasis 
cannot be reestablished, apoptosis could be induced [19]. In the current study the up-regulation of 
PDIA3 (spot 10) was a response to ER stress resulting from 11-dehydrosinulariolide treatment. It is 
speculated the accumulation of misfolded protein caused apoptosis of CAL-27 cells.  
2.5.2. 60 kDa Heat Shock Protein (Hsp60) 
Hsp60 has been shown to be connected with many aspects of cell functions such as protein folding 
and assembling of polypeptide chains in mitochondria [20]. Hsp60 exists widely in nature. It acts as 
chaperones to enhance cell survival under physiological stresses [21]. When Hsp60 is over-expressed, it 
protects cells from ischemia/hypoxic/oxidative injury to maintain mitochondrial integrity, to suppress 
mitochondrial membrane permeability, and to inhibit apoptotic and necrotic cell death [22]. It was 
reported that acute ablation of Hsp60 by small interfering RNA induces mitochondrial dysfunction, 
destabilizes  mitochondrial  pool  of  survivin,  and  activates  both  p53-dependent  and  mitochondrial 
apoptosis [23]. In this study, the down-regulation of Hsp60 after 11-dehydrosinulariolide treatment is an 
indication of the anti-cancer effect which may be related with p53-dependent or mitochondrial apoptosis 
in CAL-27 cells.  
2.5.3. 78 kDa Glucose-Regulated Protein (GRP78) 
GRP78 (spot 3) was found to be down-regulation by 11-dehydrosinulariolide treated in the study. 
GRP78 is a constitutively expressed resident protein of the endoplasmic reticulum (ER) in all eukaryotic 
cells. It is a member of the highly conserved Hsp70 family and is involved in polypeptide translation, Mar. Drugs 2011, 9  
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protein folding, and protein degradation [24]. Studies indicated that suppression of the stress-mediated 
induction of GRP78 could accelerate apoptosis, inhibit tumor growth, and increase the cytotoxicity of 
chronically hypoxic cells [25–27]. Down-regulation of GRP78 caused by interfering RNA leads to a 
slowdown of cell growth in glioma [28]. It has been reported that GRP78 could inhibit cytochrome 
c-mediated caspase activation in a cell-free system and caspase-mediated cell death [29]. It is speculated 
that  the  expression  of  GRP78  after  the  11-dehydrosinulariolide  treatment  is  related  with  caspase 
activation or ER stress response in CAL-27 cells. 
2.5.4. Heterogeneous Nuclear Ribonucleoprotein F (hnRNP F) 
HnRNP F is highly expressed in tumor cells except in hepatocellular carcinoma [30]. It is a member 
of the hnRNP family which plays roles in transcription, RNA editing, and translation. HnRNP F is 
capable  of  catalyzing  splicing  events  in  both  viral  [31–34]  and  nonviral  transcripts  [35–37]  and 
modulating the splicing of apoptotic regulator Bcl-x [35]. The elevated expression of Bcl-XL is related to 
decreased apoptosis in cancer cells, increased risk of metastasis, increased resistance to chemotherapeutic 
drugs, and poor clinical outcome [38,39]. On the other hand, Bcl-Xs can induce apoptosis and help 
sensitize cells to chemotherapeutic agents [35]. 
In this study, the down-regulation of hnRNP F (spot 4) in CAL-27 cells after 11-dehydrosinulariolide 
treatment might be correlated with decreased expression of Bcl-XL and increased apoptosis. 
2.5.5. Prohibitin 
Prohibitins are evolutionary conserved proteins that are localized in mitochondria. They are also 
involved in transcriptional regulation [40,41], apoptosis [42,43], regulation of cellular signal [44], and 
mitochondrial  biogenesis  [45,46].  Translocation  of  prohibitin  to  mitochondria  accompanies  a 
simultaneous translocation of the p53 protein. It has been reported that p53 can translocate to the 
mitochondria in response to apoptosis [47–49]. It has been reported that prohititin has the potential to be 
an anti-proliferative protein, a tumor suppressor, or a regulator for cell progression and apoptosis [50]. 
The proteomic data in this study indicated that the expression of prohibitin was up-regulated in CAL-27 
cells treated with 11-dehydrosinulariolide. This up-regulation is possibly associated with the induction 
of p53 export and the subsequent apoptosis. 
2.5.6. Ubiquinol Cytochrome c Reductase Complex Core Protein 1 (UQCRC1) 
The  expression  of  UQCRC1  (spot  16)  was  down-regulated  in  CAl-27  cells  treated  with 
11-dehydrosinulariolide. UQCRC1, a key subunit of the cytochrome bc1 complex (complex III) of the 
mitochondrial respiratory chain, may mediate the formation of the complex between cytochromes c and 
c1 [51]. Complex III is responsible for generating an electrochemical potential coupled to ATP synthesis 
for  transferring  electrons  from  ubiquinol  to  cytochrome  c.  There  were  repots  indicated  that  some 
mitochondrial  myopathies  were  caused  by  deficiency  of  complex  III  [52,53].  Dysfunction  of 
mitochondrial can result in excessive production of reactive oxygen species to stimulate the release of 
chtochrome c from mitochondrial intermembrane space to the cytosol and to trigger the transduction Mar. Drugs 2011, 9  
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pathway of apoptosis [54,55]. It has been reported that mitochondrial oxygen radical formation could be 
regulated by the uniquinol/bcl redox couple [56]. The amplification or over-expression of UQCRC1 
might  create  a  stressful  cellular  environment.  Energetic  metabolism  is  another  function  of  the 
mitochondrial  respiratory  chain.  Therefore,  amplification  or  over-expression  of  UQCRC1  might 
contribute to the rapid proliferation of cancer cells by rapid synthesis of ATP. The functions of some 
anticancer drugs are to inhibit electron transport in mitochondria at the levels of complex III [57,58]. 
Since UQCRC1 is a key subunit of complex III, modulation of this protein may contribute to cancer 
characteristics.  Based  on  the  results  of  this  study,  it  is  proposed  that  increased  concentration  of 
11-dehydrosinulariolide resulted in a  progressive  inhibition of O2  uptake and decreased UQCRC1 
expression in CAL-27 cells and, consequently, caused mitochondria dysfunction and subsequently 
triggered the transduction pathway of apoptosis. 
3. Experimental Section 
3.1. Cell Culture and Treatment with 11-Dehydrosinulariolide 
CAL-27 cells were grown in DMEM with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium 
bicarbonate  and  4.5  g/L  glucose,  supplemented  with  10%  (v/v)  FBS,  100  units/mL  penicillin, 
100 µ g/mL streptomycin, 1 mM sodium pyruvate, and 0.01 mg/mL human transferring in a humidified 
atmosphere with 5% CO2 in air at 37 ° C. When cells reached above 70% confluency, subculture was 
conducted at a split ratio of 1:6. CAL-27 cells were cultured in a 10 cm dish for each assay. The isolation 
of 11-dehydrosinulariolide from the soft coral Sinularia leptoclado was carried out according to the 
literature procedures [11]. Control cultures were made by adding DMSO at the same final concentration 
as  in  the  treated  samples  (0.01%  v/v).  Cells  were  added  with  four  different  concentrations  of 
11-dehydrosinulariolide (0.5 µ g/mL, 1.0 µ g/mL, 1.5 µ g/mL, and 2.0 µg /mL) and harvested after 24 h 
incubation. All the experiments were repeated three times to confirm reproducibility. 
3.2. MTT Assay  
The cytotoxic effect of 11-dehydrosinulariolide against CAL-27 cells was determined by the MTT 
assay. CAL-27 cells (1 ×  10
5/cm
2) were incubated in 96 well microtiter plates. Treatment with various 
concentrations of 11-dehydrosinulariolide (0.5 µg /mL, 1.0 µg /mL, 1.5 µg /mL, and 2.0 µ g/mL) followed 
for 24 h. Each well was added with 50 µL  MTT solution (1 mg/mL in PBS) and the plates were 
incubated for 4 h at 37 °C . To achieve solubility of purple-blue MTT formazan crystals in viable cells, 
200 µL  of DMSO was aged to each well. The absorbance was read at 595 nm on a microtiter plate 
ELISA reader with DMSO as blank. Analysis of variance (ANOVA) followed by the Tukey-Kramer test 
on GraphPad InStat 3 (San Diego, CA, USA) to determine whether there were significant differences  
(p  0.05) [59]. 
3.3. Apoptosis and Cell Cycle Analysis 
Apoptosis and cell cycle arrest induced by 11-dehydrosinulariolide for 6 h were determined by using 
an Annexin V-FITC and PI Apoptosis Detection Kit (BioVision, USA ) according to manufacturer’s Mar. Drugs 2011, 9  
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instructions. Assessment of samples was accomplished FACSauto flow cytometer (Becton Dickinson, 
USA). Data analysis was carried out with WinMDI software (ver. 2.9, windows Multiple Document 
Interface, Flow Cytometry Application). The cells in the FITC-positive and PI-negative fractions were 
defined as apoptotic cells.  
3.4. Wound Healing Assay 
CAL-27 cells were plated in a 6-well plate. After the cells grew to confluence, a scratch/wound was 
made  with  a  pipette  tip  in  each  of  the  wells.  Cells  were  washed  with  PBS  and  refreshed  with 
FBS-containing medium. Microscopic fields were photographed at the initial point (0 h) and thereafter. 
3.5. Protein Extraction and Estimation  
CAL-27 cells were untreated or treated with different concentrations of 11-dehydrosinulariolide  
(0, 0.5, 1.0 and 1.5 µg /mL) for 24 h and then lysed with Cell Extraction Buffer (BioSource International, 
Camarillo, CA, USA) and protease inhibitor cocktail (Sigma).The total protein in the supernatant was 
then  precipitated  out  for  overnight  (−20  °C )  by  triple  the  volume  of  10%  TCA/Acetone  solution 
containing 20 mM DTT. After centrifugation at 8000 rpm for 30 min at 4 °C , the supernatant was 
discarded. The pellet was suspended in a rehydration buffer (6 M urea, 2 M thiourea, 0.5% CHAPS, 
0.5% IPG buffer, 20 mM DTT, and 0.002% bromophenol blue) at 4 °C  for overnight. The IPG buffer 
was  purchased  from  GE  Healthcare.  The  protein  contents  were  determined  using  2-D  Quant  Kit  
(GE Healthcare). 
3.6. Two-Dimensional Gel Electrophoresis 
The first dimension electrophoresis (isoelectric focusing) was performed on GE Healthcare Ettan 
IPGphor 3 at 20 °C  with a current limit of 30 A per strip. A sample was dissolved in a rehydration buffer 
as described above and applied on an IPG strip in a strip holder. Every 11-cm IPG strip (pI 4–7, 
Immobiline DryStrip) was rehydrated at 30 V for 12 h and then focused according to the preset program: 
200 V (2 h), 500 V (2 h), 1000 V (2 h), 4000 V (1 h), 8000 V (4 h), until the total Vh reached 39,400. The 
equilibrated strip was placed on the top of a SDS-PAGE gel (12.5%), sealed with 0.5% agarose, then the 
second dimension electrophoresis was run at 150 V for 6.5 h. Electrophoretic unit used for the second 
dimension electrophoresis was SE 600 Ruby (Hoeffer). 2-DE images were made in triplicate for each 
sample and normalized prior to statistical analysis.  
3.7. Protein Identification by LC-MS/MS 
In-gel Digestion: A protein spot of interest was excised into a piece of 1 mm ×  1 mm, then placed in a 
microcentrifuge tube. A 100 μL of 50 mM DTT in 25 mM ammonium bicarbonate (pH 8.5) was added to 
the tube which was shaken at 37 ° C for 1 h. After removing excess DTT in supernatant, a 100 μL of 
100 mM Iodoacetamide (IAA) in 25 mM ammonium bicarbonate (pH 8.5) was added to the tube which 
was then shaken for 30 min at RT in dark. The excess IAA in supernatant was removed. A 100 μL of 
50% acetonitrile in 25 mM ammonium bicarbonate buffer (pH 8.5) was added and then the gel piece was 
soaked for 15 min followed a complete removal of the buffer. A 0.1 µ g of trypsin in 10 μL 25 mM Mar. Drugs 2011, 9  
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ammonium bicarbonate (pH 8.5) was added to the gel piece. Digestion was run for 16 h at 37 ° C. The 
solution was sonicated for 20 s to release the tryptic peptides from the gel. The peptide solution was then 
concentrated for the LC-MS/MS analysis. 
LC-MS/MS  analysis:  A  peptide  mixture  was  separated  by  nanoflow  reversed  phase  C18 
chromatography on nano LC using the Agilent 1200 System and PepMap100 C18, 75 μm ×  15 cm (3 μm) 
nanoLC column or HPLC using the Agilent NanoLC 1200 System and Agilent Zobax 2.1 mm ×  150 mm 
C18 column. LC-MS/MS analysis employed a 10 min online trapping and desalting step followed by a 
60 min 5–40% mobile B gradient at nano flow and a 15 min 5–40% mobile B gradient at higher flow 
(mobile B = 98% ACN, 0.1% formic acid). Samples were analyzed on the AB SCIEX QTRAP
® 5500Q 
mass spectrometer (Applied Biosystems, CA, USA). The scan range was from m/z 100 to1000 for MS. 
The raw data was processed into a text file format of WIFF with Analyst 1.5.1.  
3.8. Western Blotting Analysis 
After SDS-PAGE analysis of the treated samples and the controls under reducing conditions, the 
proteins on gel were transferred to a PVDF membrane (Millipore) for 1.5 h at 400 mA using Transphor 
TE 62 (Hoeffer). The membranes were then incubated with rabbit polyclonal antibodies against human 
GRP-78, Hsp60, PDIA3, UQCRC1 and GAPDH (ProteinTech Group, USA) and rabbit monoclonal 
antibody anti human prohibitin(Epitomics, California, USA) at 4 °C  for 2 h. The membranes were 
washed three times in PBST (10 mM NaH2PO4, 130 mM NaCl, 0.05% Tween 20), then probed with the 
second Ab (goat anti-rabbit and horseradish peroxidase conjugate, 1:5000 in blocking solution) for 1 h. 
After it was washed with PBST for three times, the enzyme activity on the blot was visualized through 
chemiluminesence by adding ECL Western Blotting Reagents (Pierce).  
4. Conclusion 
The  anti-tumor  effects  of  11-dehydrosinulariolide  on  CAL-27  cells  have  been  extensively 
investigated in this study. In the MTT assay for cell proliferation, the inhibition ratio increased as  
the  concentration  of  11-dehydrosinulariolide  increased.  When  a  concentration  of  1.5  µg /mL  of 
11-dehydrosinulariolide was added to CAL-27 cells, the viability of cells was reduced to a level of 
70% of the control. The effect of 11-dehydrosinulariolide on CAL-27 cell was also examined by wound 
healing assay. The wound healing function decreased as the concentration of 11-dehydrosinulariolide 
increased. The cytotoxicity effect of 11-dehydrosinulariolide for the induction of apoptosis of CAL-27 
cells  has  also  been  studied.  The  results  indicated  that  treatment  with  11-dehydrosinulariolide 
significantly induced both early and late apoptosis of CAL-27 cells, observed by flow cytometric 
measurement and microscopic fluorescent observation. Comparative proteomic analysis provided an 
extensive and effective approach to detect changes of protein expression profiling of CAL-27 cells 
treated  with  11-dehydrosinulariolide.  A  total  of  28  differential  proteins  (12  up-regulated  and 
16 down-regulated) in the CAL-27 cells treated with 11-dehydrosinulariolide have been identified by 
LC-MS/MS analysis. The differential proteins, which were defined as the proteins showing a more than 
1.5 fold intensity difference in the 2-DE maps between the treated CAL-27 cells and the control samples, 
including protein disulfide-isomerase A3, 78 kDa glucose-regulated protein, peptidyl-prolyl cis-trans 
isomerase A, prohibitin, heterogeneous nuclear ribonucleoprotein F, 60 kDa heat shock protein, ubiquinol Mar. Drugs 2011, 9  
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cytochrome c reductase complex core protein 1, 40S ribosomal protein SA, transitional endoplasmic 
reticulum  ATPase,  fructose-bisphosphate  aldolase  A,  and  nascent  polypeptide-associated  complex 
subunit alpha. Some differential proteins are associated with cell proliferation, apopotosis, protein 
synthesis, protein folding, and energy metabolism.  
The  results  of  this  study  indicated  that  11-dehydrosinulariolide  could  inhibit  CAL-27  cell 
proliferation by exerting effects on regulating the expressions of some specific proteins. Identification 
and  characterization  of  some  functionally  modulated  proteins  in  anti-cell-proliferation  could  help 
understand the long-term effects of 11-dehydrosinulariolide on CAL-27 cells at the molecular level. 
Further studies of these proteins will help unveil the anti-tumor mechanisms of the treatment with 
11-dehydrosinulariolide and thus benefit the development of new target drugs for oral squamous cell 
carcinoma (OSCC). 
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